These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 25126672

  • 1. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
    Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk-Schulz IM, Jobsen JJ, Creutzberg CL, Smit VT.
    Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
    [Abstract] [Full Text] [Related]

  • 2. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
    Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA.
    Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
    [Abstract] [Full Text] [Related]

  • 3. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
    Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1142-50. PubMed ID: 23781004
    [Abstract] [Full Text] [Related]

  • 4. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
    Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P.
    Int J Radiat Oncol Biol Phys; 2015 Mar 01; 91(3):530-9. PubMed ID: 25680597
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
    Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL, PORTEC Study Group.
    Lancet; 2010 Mar 06; 375(9717):816-23. PubMed ID: 20206777
    [Abstract] [Full Text] [Related]

  • 9. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F, Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, Brucker SY, Wallwiener D, Schönfisch B, Greif K, Lax S, Staebler A, Kommoss S.
    J Cancer Res Clin Oncol; 2017 Feb 06; 143(2):255-262. PubMed ID: 27695947
    [Abstract] [Full Text] [Related]

  • 10. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MP, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Amant F, Massuger LF, Pijnenborg JM.
    Br J Cancer; 2016 Sep 06; 115(6):716-24. PubMed ID: 27505134
    [Abstract] [Full Text] [Related]

  • 11. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM, Visser NCM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Werner HMJ, Amant F, Massuger LFAG, Pijnenborg JMA.
    Int J Gynecol Cancer; 2018 Mar 06; 28(3):514-523. PubMed ID: 29324536
    [Abstract] [Full Text] [Related]

  • 12. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial.
    Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, Lybeert ML, Slot A, Lutgens LC, Stenfert Kroese MC, Beerman H, van Lent M, postoperative Radiation Therapy in Endometrial Carcinoma Trial.
    J Clin Oncol; 2004 Apr 01; 22(7):1234-41. PubMed ID: 15051771
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T.
    Mod Pathol; 2016 Feb 01; 29(2):174-81. PubMed ID: 26743472
    [Abstract] [Full Text] [Related]

  • 14. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
    Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC, Han ES.
    Gynecol Oncol; 2016 May 01; 141(2):336-340. PubMed ID: 26861585
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.